Essentially, cereblon and its target proteins can change shape to form a complex with the cereblon, the target, and the ...

Shares of Monte Rosa Therapeutics (NASDAQ:GLUE) rallied 49% Monday morning after the biotech signed an exclusive license deal with Novartis (NYSE:NVS) to advance its VAV1-directed molecular glue ...

Monte Rosa’s AI/ML-powered insights dramatically increase targetable protein space for molecular glue degraders, unlocking ...

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, has made significant advancements in drug discovery as highlighted in a cover article published in Science. The research ...

Monte Rosa Therapeutics, Inc. secured a $150 million upfront partnership with Novartis to develop MRT-6160 for immune-mediated conditions, with a potential $2.1 billion in milestone payments.

Monte Rosa Therapeutics signed a development and commercialization deal with Novartis that could pay the biotech up to $2.1 billion. The agreement is for Monte Rosa's MRT-6160 drug and other ...

Shares of Monte Rosa Therapeutics (GLUE) have gained 22.5% over the past four weeks to close the last trading session at $5.01, but there could still be a solid upside left in the stock if short-term ...

Explore Monte Rosa Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for GLUE.

Monte Rosa Therapeutics' stock falls as MRT-2359 faces challenges in targeting CRPC. Click here to read an analysis of GLUE stock now.

From what we can see, insiders were net buyers in Monte Rosa Therapeutics, Inc.'s (NASDAQ:GLUE ) during the past 12 months. That is, insiders acquired the stock in greater numbers than they sold it.

Monte Rosa’s AI/ML-powered insights dramatically increase targetable protein space for molecular glue degraders, unlocking new opportunities to address previously undruggable therapeutic targets ...

BOSTON, July 03, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today ...